Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data
Joshua J. Gagne(Johnson & Johnson (United States)), Shirley Wang(Harvard University), Abdurrahman Abdurrob(Brigham and Women's Hospital), Bogdan Balas(Roche (Switzerland)), Raymond G. Schlienger(Novartis (Switzerland)), Mehdi Najafzadeh(Brigham and Women's Hospital), Sara Bruce Wirta(Novartis (Switzerland)), Theodore Tsacogianis(Brigham and Women's Hospital), Chun‐Lan Chang(Novartis (United States)), F Calado(Novartis (Switzerland)), Stuart Turner(Novartis (United States)), James R. Rogers(Brigham and Women's Hospital)
Cited by 1
Related Papers
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications
|European Journal of Clinical Pharmacology|2014|162
Intraseason Waning of Influenza Vaccine Effectiveness
|Clinical Infectious Diseases|2018|123
Real-World Treatment Patterns of Sacubitril/Valsartan: A Longitudinal Cohort Study in Germany
|European Journal of Heart Failure|2019|66
Burden of heart failure on caregivers in China: results from a cross-sectional survey
|Drug Design Development and Therapy|2018|48